Nialamide
CAS: 51-12-7
Ref. 3D-AAA05112
| 1g | Discontinued | ||
| 1mg | Discontinued | ||
| 10mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- 1-[2-(Benzylcarbamoyl)ethyl]-2-isonicotinoylhydrazine
- Espril
- Isonicotinic acid, 2-[2-(benzylcarbamoyl)ethyl]hydrazide
- N1-Beta-Benzylcarbamoyl-ethyl-N2-isonicotinoyl-hydrazine
- N<sub>1</sub>-Beta-Benzylcarbamoyl-ethyl-N<sub>2</sub>-isonicotinoyl-hydrazine
- Nialamid
- Nialamida
- Niamid
- Niamidal
- Niamide
- See more synonyms
- Niaquitil
- Niazin
- Novazid
- Nsc 124514
- Nuredal
- Nyezin
- 4-Pyridinecarboxylic acid, 2-[3-oxo-3-[(phenylmethyl)amino]propyl]hydrazide
- N-benzyl-3-(2-isonicotinoylhydrazino)propionamide
- N-benzyl-3-[2-(pyridin-4-ylcarbonyl)hydrazinyl]propanamide
Nialamide is an experimental drug that has been shown to have a matrix effect. It inhibits the enzyme activity of dopamine and serotonin, which are neurotransmitters that regulate mood and behavior. Nialamide also increases the concentrations of 5-hydroxytryptamine (5-HT) in the brain, which may be due to its ability to act as a 5-HT agonist. The pharmacological effects of nialamide are similar to those of drugs that are used for Parkinson's disease and depression. Nialamide has been shown to increase locomotor activity in rats, as well as systolic pressure in rats. This drug is also able to inhibit trigeminal nerve stimulation, suggesting that it may be useful for treating migraines or other neurological disorders linked with this type of stimulus.
